In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.
Request InsightsPurchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively. Request Insights
IN THE NEWS
The global bivalirudin and desmopressin market is estimated to garner significant revenue by the end of 2031 by growing at a CAGR of ~5% over the forecast period, i.e., 2022 – 2031. Further, the market generated modest revenue in the year 2021. Increasing demand for bivalirudin is being driven by its application in the treatment of cancer and cardiovascular disease. In addition, rising incidences of cardiovascular diseases worldwide are expected to drive market growth during the forecast period. According to the World Health Organization, Cardiovascular disease is one of the leading causes of death worldwide. CVDs caused an estimated 17.9 million deaths in 2019, which accounted for 32% of all deaths worldwide. Furthermore, increasing demand for desmopressin owing to its use for nocturia and bedtime wetting is expected to drive global bivalirudin and desmopressin market growth. Desmopressin medicines have also been extensively used in conditions such as diabetes insipidus, which causes the body to produce excessive amounts of urine.
Get more information on this report: Request Sample PDF
Bivalirudin is a synthetic residue compound that inhibits direct thrombin. Especially in people with severe chest pain or those undergoing angioplasty, it prevents the formation of blood clots. Also, heart attack patients who undergo percutaneous coronary intervention are treated with this drug. Likewise, desmopressin is an artificial replacement for vasopressin and acts by limiting the amount of water that is excreted in the urine. Moreover, awareness programs and initiatives regarding bedwetting and enuresis medical conditions are market trends expected to propel the demand for desmopressin during the forecast period. For instance, in September 2021, an organization launched a public awareness campaign to raise awareness about the problem of enuresis in children. In 2015, World Bedwetting Day was initiated to promote awareness of enuresis as a treatable medical condition.
The global bivalirudin and desmopressin market is segmented and analyzed for demand and supply by application into percutaneous coronary intervention (PCI) procedures, percutaneous transluminal coronary angioplasty (PTCA) procedures, and others. Among these, the percutaneous coronary intervention (PCI) procedure segment is anticipated to capture the largest market size in the global bivalirudin and desmopressin market owing to the rising incidences of adverse cardiovascular (CVDs) and heart diseases among population. For instance, cardiovascular disease (CVD) was the leading cause of death in the United States in 2018, followed by stroke (17%), high blood pressure (11%), heart failure (9.5%), arteries diseases (3%), and other CVD (17.2%). PCI procedures are intended to reduce adverse cardiovascular diseases. PCI is further enhanced by antithrombotic and antiplatelet therapies as an adjunct to reduce MACE rates. This factor is expected to fuel the segment growth during the forecast period.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Regionally, the global bivalirudin and desmopressin market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2031. Coronary artery disease (CAD) prevalence among the population resulted in increasing percutaneous coronary intervention (PCI) procedures in the region. It was observed that nearly 960,000 percutaneous coronary intervention procedures are performed each year in the United States. Percutaneous coronary intervention (PCI) also known as angioplasty, is a procedure to open a blocked or narrowing artery. Moreover, increasing cases of cardiovascular diseases and heart diseases in the region are expected to drive market growth during the forecast period. For instance, there were approximately 695,000 deaths caused by heart disease in the United States in 2020.
The global bivalirudin and desmopressin market is further classified on the basis of region as follows:
Our in-depth analysis of the global bivalirudin and desmopressin market includes the following segments:
|
By Application |
|
|
By End User |
|
FREQUENTLY ASKED QUESTIONS
Rising prevalence of cardiovascular diseases along with increasing number of elderly people suffering from nocturia are the major factors driving the growth of the bivalirudin and desmopressin market.
The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2022 – 2031.
High cost associated with the bivalirudin drug along with the health concerns such as bleeding, difficulty breathing, and sudden numbness are challenges expected to hinder market growth.
The market in North America is projected to hold the largest market share by the end of 2031 and provide more business opportunities in the future.
The major players in the market are Pfizer, Inc., Hainan Shuangcheng Pharmaceuticals Co. Ltd., AmbioPharm Inc., Abott India Limited, The Medicines Company, Sun Pharmaceuticals Industries Limited, Ferring Pharmaceuticals, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by application, end user, and by region.
The percutaneous coronary intervention (PCI) procedures segment is anticipated to garner the largest market size by the end of 2031 and display significant growth opportunities.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions | LOB
Copyright © 2022 Research Nester. All Rights Reserved
